Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics Inc (ARQT)
:ARQT
ARQT Analyst Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARQT Stock 12 Month Forecast
Average Price Target
$21.41
▲(39.75% Upside)
| Highest Price Target$29.00 | Average Price Target$21.41 | Lowest Price Target$14.29 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$15.5
Hold
1.17%
Upside
Reiterated
08/07/25
Arcutis Biotherapeutics' overall score is driven by strong revenue growth and positive technical indicators. However, ongoing net losses, negative cash flows, and valuation concerns weigh heavily on the score. The earnings call provided a positive outlook with significant FDA approvals, but challenges remain in achieving profitability and securing Medicare coverage.
Goldman Sachs
$14.29
Hold
-6.72%
Downside
Initiated
07/24/25
Guggenheim
$29
Buy
89.30%
Upside
Reiterated
07/21/25
Jefferies
$20→$23
Buy
50.13%
Upside
Reiterated
07/21/25
Mizuho Securities
$21
Buy
37.08%
Upside
Reiterated
07/08/25
Morgan Stanley
$19→$20
Buy
30.55%
Upside
Initiated
07/02/25
H.C. Wainwright
$19
Buy
24.02%
Upside
Reiterated
06/09/25
TD Cowen
$20
Buy
30.55%
Upside
Reiterated
06/03/25
Needham
$20
Buy
30.55%
Upside
Reiterated
05/22/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$15.5
Hold
1.17%
Upside
Reiterated
08/07/25
Arcutis Biotherapeutics' overall score is driven by strong revenue growth and positive technical indicators. However, ongoing net losses, negative cash flows, and valuation concerns weigh heavily on the score. The earnings call provided a positive outlook with significant FDA approvals, but challenges remain in achieving profitability and securing Medicare coverage.
Goldman Sachs
$14.29
Hold
-6.72%
Downside
Initiated
07/24/25
Guggenheim
$29
Buy
89.30%
Upside
Reiterated
07/21/25
Jefferies
$20→$23
Buy
50.13%
Upside
Reiterated
07/21/25
Mizuho Securities
$21
Buy
37.08%
Upside
Reiterated
07/08/25
Morgan Stanley
$19→$20
Buy
30.55%
Upside
Initiated
07/02/25
H.C. Wainwright
$19
Buy
24.02%
Upside
Reiterated
06/09/25
TD Cowen
$20
Buy
30.55%
Upside
Reiterated
06/03/25
Needham
$20
Buy
30.55%
Upside
Reiterated
05/22/25
Best Analysts Covering Arcutis Biotherapeutics
1 Month
xxx
Success Rate
20/43 ratings generated profit
Average Return
+4.55%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.51% of your transactions generating a profit, with an average return of +4.55% per trade.
3 Months
xxx
Success Rate
21/43 ratings generated profit
Average Return
+1.56%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.84% of your transactions generating a profit, with an average return of +1.56% per trade.
1 Year
Success Rate
12/19 ratings generated profit
Average Return
+36.69%
reiterated a buy rating 3 months ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +36.69% per trade.
2 Years
xxx
Success Rate
13/19 ratings generated profit
Average Return
+65.71%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +65.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARQT Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
4
4
2
3
6
Buy
17
16
20
18
12
Hold
7
7
8
6
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
27
30
27
29
Each month's total comprises the sum of three months' worth of ratings.
ARQT Financial Forecast
ARQT Stock Forecast FAQ
What is ARQT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcutis Biotherapeutics Inc’s 12-month average price target is 21.41.
What is ARQT’s upside potential, based on the analysts’ average price target?
Arcutis Biotherapeutics Inc has 39.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARQT a Buy, Sell or Hold?
Arcutis Biotherapeutics Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Arcutis Biotherapeutics Inc’s price target?
The average price target for Arcutis Biotherapeutics Inc is 21.41. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $14.29. The average price target represents 39.75% Increase from the current price of $15.32.
The highest analyst price target is $29.00 ,the lowest forecast is $14.29. The average price target represents 39.75% Increase from the current price of $15.32.
What do analysts say about Arcutis Biotherapeutics Inc?
Arcutis Biotherapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ARQT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.